Influenza-like Illness
18
3
4
12
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 18 trials
100.0%
+13.5% vs benchmark
33%
6 trials in Phase 3/4
17%
2 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (18)
A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD
Clinical Assessment of Respiratory Events for Kids: Integrating Diagnostics and Stewardship
Effectiveness and Implementation of a National Guideline for Acute Respiratory Tract Infections to Reduce Antibiotic Prescribing in Swiss Primary Care
ORCHARDS-AIR Study
The Fever Clinic Acute Respiratory Cohort
FluSAFE: Flu SMS Alerts to Freeze Exposure
Adjuvanted Influenza Vaccination Year 2 Follow-On Survey
Adjuvanted Influenza Vaccination in U.S. Nursing Homes
Evaluation of Psychometric Testing Properties of Severity Symptom Grading Scale of Influenza Infection: Flu-PRO Stage III
Non-specific Effects of Rabies Vaccine
Biobran/MGN-3 Increases Innate Resistance and Reduces the Incidence of Influenza-like Illnesses
Kent State University / Price Chopper Employee Wellness Study
Probiotic and Influenza Vaccination to Reducing Influenza-like Illness Incident in Elderly
Impact of Rapid Flu Testing in BMC ED
Characterization of Influenza-like Illness in Mexico
Nasal Specimen Collection Study in Patients With ILI and/or ARI in an Outpatient Setting
Direct and Indirect Benefits of Influenza Vaccination in Schools and Households
REDucing Influenza Among University Students, University of California at Berkeley